Blood group distribution in prostatic cancer patients

Abstract

Blood group distribution in 264 Stage D relapsing patients from the National Prostatic Cancer Project was analyzed. No significant differences were found in distribution of blood groups in prostatic cancer patients as compared to the control population. This study does not support the observation of others of a relationship between blood group A and susceptibility to carcinoma of the prostate. Other patient groups may, however, be of value in searching for this relationship.

The role of the histoblood ABO group in cancer

“…An analysis of multiple reports of the link between blood type and benign hyperplasia found no association with any of the blood types in this premalignant condition [60]. Lack of association between blood type and prostate cancer risk or survival has also been reported [61,62]. At the tissue level, while one study suggests that loss of antigen expression increases with tumor progression [63], a separate study found that lack of antigen expression of histoblood group antigens in prostate tumor tissue is not a marker of invasion [64].…”